针对新发的耐多药/广泛耐药结核病（MDR/XDR-TB）的老抗生素。
Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).
机构信息
Institut Hospital-Universitaire (IHU) Mediterranée Infection, AP-HM, Marseille, France; Aix-Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France.
Institut Hospital-Universitaire (IHU) Mediterranée Infection, AP-HM, Marseille, France; Aix-Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), UM63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France.
出版信息
Int J Antimicrob Agents. 2017 May;49(5):554-557. doi: 10.1016/j.ijantimicag.2017.02.008. Epub 2017 Mar 21.
Recently, multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic challenge. In addition to drug resistance, drug adverse events, intravenous delivery, cost and availability of some antibiotics in low-income countries have led to a look back to old drugs, especially those efficient against closely related organisms such as Mycobacterium leprae. Here we review the available drugs that respect the conditions above and could be upgraded to first-line therapy for treating MDR-TB and extensively drug-resistant tuberculosis (XDR-TB).
最近，耐多药结核病（MDR-TB）已成为治疗的挑战。除了耐药性之外，药物不良反应、静脉给药以及在低收入国家中一些抗生素的成本和可获得性，使得人们重新关注旧药物，特别是那些对密切相关的生物体如麻风分枝杆菌有效的药物。在这里，我们回顾了符合上述条件的可用药物，这些药物可能被升级为治疗耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）的一线治疗药物。
Zotero 插件